BR112019001247A2 - anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo isolado ou fragmento de ligação ao antígeno do mesmo, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para produzir o anticorpo ou fragmento de ligação ao antígeno, composição, e, método de inibição da ativação do complemento da via alternativa em um mamífero. - Google Patents
anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo isolado ou fragmento de ligação ao antígeno do mesmo, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para produzir o anticorpo ou fragmento de ligação ao antígeno, composição, e, método de inibição da ativação do complemento da via alternativa em um mamífero.Info
- Publication number
- BR112019001247A2 BR112019001247A2 BR112019001247A BR112019001247A BR112019001247A2 BR 112019001247 A2 BR112019001247 A2 BR 112019001247A2 BR 112019001247 A BR112019001247 A BR 112019001247A BR 112019001247 A BR112019001247 A BR 112019001247A BR 112019001247 A2 BR112019001247 A2 BR 112019001247A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigen
- binding fragment
- antibody
- isolated
- cloning
- Prior art date
Links
- 230000024203 complement activation Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 3
- 102000036639 antigens Human genes 0.000 title 3
- 108091007433 antigens Proteins 0.000 title 3
- 239000012634 fragment Substances 0.000 title 3
- 238000000034 method Methods 0.000 title 2
- 241000124008 Mammalia Species 0.000 title 1
- 108091028043 Nucleic acid sequence Proteins 0.000 title 1
- 238000010367 cloning Methods 0.000 title 1
- 239000013599 cloning vector Substances 0.000 title 1
- 239000013604 expression vector Substances 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F17/00—Compounds of rare earth metals
- C01F17/20—Compounds containing only rare earth metals as the metal element
- C01F17/206—Compounds containing only rare earth metals as the metal element oxide or hydroxide being the only anion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/77—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/77—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals
- C09K11/7728—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals containing europium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
- H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/50—Solid solutions
- C01P2002/52—Solid solutions containing elements as dopants
- C01P2002/54—Solid solutions containing elements as dopants one element only
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/80—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
- C01P2002/84—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by UV- or VIS- data
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662369674P | 2016-08-01 | 2016-08-01 | |
US201662419420P | 2016-11-08 | 2016-11-08 | |
US201762478336P | 2017-03-29 | 2017-03-29 | |
PCT/US2017/044714 WO2018026722A1 (en) | 2016-08-01 | 2017-07-31 | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019001247A2 true BR112019001247A2 (pt) | 2019-06-25 |
Family
ID=61073545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019001247A BR112019001247A2 (pt) | 2016-08-01 | 2017-07-31 | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo isolado ou fragmento de ligação ao antígeno do mesmo, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para produzir o anticorpo ou fragmento de ligação ao antígeno, composição, e, método de inibição da ativação do complemento da via alternativa em um mamífero. |
Country Status (25)
Country | Link |
---|---|
US (4) | US10639369B2 (pt) |
EP (1) | EP3490603A4 (pt) |
JP (3) | JP6971306B2 (pt) |
KR (3) | KR102553777B1 (pt) |
CN (4) | CN116333146A (pt) |
AU (4) | AU2017306069B2 (pt) |
BR (1) | BR112019001247A2 (pt) |
CA (3) | CA3122348A1 (pt) |
CL (1) | CL2019000230A1 (pt) |
CO (1) | CO2019001212A2 (pt) |
CR (1) | CR20190105A (pt) |
CU (1) | CU24568B1 (pt) |
EC (1) | ECSP19015192A (pt) |
GE (1) | GEP20247593B (pt) |
IL (3) | IL298690B2 (pt) |
JO (6) | JOP20170154B1 (pt) |
MA (1) | MA45798A (pt) |
MX (3) | MX2019000965A (pt) |
PE (1) | PE20190389A1 (pt) |
PH (1) | PH12019500204A1 (pt) |
SA (1) | SA519400950B1 (pt) |
SG (3) | SG10202010279YA (pt) |
TW (4) | TW202334243A (pt) |
UY (1) | UY37349A (pt) |
WO (1) | WO2018026722A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
KR102632860B1 (ko) | 2017-03-01 | 2024-02-02 | 아칠리온 파르마세우티칼스 인코포레이티드 | 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물 |
US20210215714A1 (en) * | 2018-05-25 | 2021-07-15 | Achillion Pharmaceuticals, Inc. | Complement alternative pathway-associated nephropathy biomarkers |
KR20210057086A (ko) | 2018-09-06 | 2021-05-20 | 아칠리온 파르마세우티칼스 인코포레이티드 | 다니코판의 형태체 형태 |
JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ, インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
KR20210093855A (ko) | 2018-09-25 | 2021-07-28 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 인자 d 억제제의 형태체 형태 |
CN110244053B (zh) * | 2019-05-09 | 2022-03-11 | 北京大学第三医院(北京大学第三临床医学院) | 用于诊断狼疮肾炎并肺动脉高压疾病的分子标志物及其用途 |
CN112812182B (zh) * | 2019-11-15 | 2023-01-06 | 深圳宾德生物技术有限公司 | 一种靶向fgfr4的单链抗体、嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用 |
KR20220131233A (ko) * | 2020-01-21 | 2022-09-27 | 상하이 바이오트로이 바이오테크니크 컴퍼니, 리미티드 | Semg2 항체 및 이의 용도 |
JP2023538914A (ja) * | 2020-08-18 | 2023-09-12 | オメロス コーポレーション | 補体因子dを検出するためのモノクローナル抗体、組成物、および方法 |
CN112950324B (zh) * | 2021-03-15 | 2022-06-03 | 重庆邮电大学 | 一种知识图谱辅助的成对排序个性化电商推荐方法及*** |
CN115304670A (zh) * | 2021-05-07 | 2022-11-08 | 华南农业大学 | 一种猫冠状病毒核衣壳蛋白的鼠源单克隆抗体及其编码基因和应用 |
WO2023173036A2 (en) * | 2022-03-10 | 2023-09-14 | Omeros Corporation | Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
US7273925B1 (en) | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
CA2391402A1 (en) * | 1999-12-02 | 2001-06-07 | Jens Christian Jensenius | Masp-3, a complement-fixing enzyme, and uses for it |
SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
ES2601143T3 (es) | 2002-07-19 | 2017-02-14 | Omeros Corporation | Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos |
ES2614274T3 (es) | 2002-09-06 | 2017-05-30 | Alexion Pharmaceuticals, Inc. | Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5 |
JP2006518749A (ja) | 2003-02-21 | 2006-08-17 | タノックス インコーポレーテッド | 虚血再灌流障害に伴う組織損傷を予防及び治療するための方法 |
DE102004017370A1 (de) | 2004-04-08 | 2005-10-27 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | PUFA-PKS Gene aus Ulkenia |
US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
BRPI0615026A8 (pt) | 2005-08-19 | 2018-03-06 | Abbott Lab | imunoglobulina de domínio variável duplo e seus usos |
CA2685714C (en) | 2007-05-31 | 2016-04-12 | University Of Washington | Inducible mutagenesis of target genes |
BR112012001070B1 (pt) | 2009-07-17 | 2022-05-03 | Omeros Corporation | Composição de polipeptídeo associado à ficolina e uso da mesma |
DK2462161T3 (en) * | 2009-08-06 | 2017-06-06 | Immunas Pharma Inc | Antibodies specifically binding to A-beta oligomers and their use |
WO2011026242A1 (en) * | 2009-09-03 | 2011-03-10 | Vancouver Biotech Ltd. | Monoclonal antibodies against gonadotropin-releasing hormone receptor |
CN102918061B (zh) * | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
US20120122107A1 (en) | 2010-11-16 | 2012-05-17 | Aarhus Universitet | Homeostatic multidomain protein, and uses for it |
WO2012151481A1 (en) * | 2011-05-04 | 2012-11-08 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement acitivation |
RS57266B1 (sr) * | 2012-04-06 | 2018-08-31 | Omeros Corp | Mešavine i postupci za inhibiranje masp-1 i/ili masp-3 u lečenju paroksizmalne noćne hemoglobinurije |
KR20220100997A (ko) * | 2012-06-18 | 2022-07-18 | 오메로스 코포레이션 | 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법 |
BR112015019603A2 (pt) * | 2013-02-20 | 2017-08-22 | Novartis Ag | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna |
ES2766762T3 (es) * | 2013-03-13 | 2020-06-15 | Prothena Biosciences Ltd | Inmunoterapia contra Tau |
ES2794088T3 (es) * | 2014-01-29 | 2020-11-17 | Dana Farber Cancer Inst Inc | Anticuerpos contra el dominio extracelular de MUC1-C (MUC1-C/ECD) |
-
2017
- 2017-07-03 JO JOP/2017/0154A patent/JOP20170154B1/ar active
- 2017-07-30 TW TW112116731A patent/TW202334243A/zh unknown
- 2017-07-30 TW TW110149487A patent/TWI820555B/zh active
- 2017-07-30 TW TW106125649A patent/TWI756248B/zh active
- 2017-07-30 TW TW110149485A patent/TW202214689A/zh unknown
- 2017-07-31 SG SG10202010279YA patent/SG10202010279YA/en unknown
- 2017-07-31 MA MA045798A patent/MA45798A/fr unknown
- 2017-07-31 SG SG10202010277SA patent/SG10202010277SA/en unknown
- 2017-07-31 IL IL298690A patent/IL298690B2/en unknown
- 2017-07-31 US US15/665,030 patent/US10639369B2/en active Active
- 2017-07-31 CN CN202210979606.9A patent/CN116333146A/zh active Pending
- 2017-07-31 CN CN202210979607.3A patent/CN116327918A/zh active Pending
- 2017-07-31 KR KR1020227010749A patent/KR102553777B1/ko active IP Right Grant
- 2017-07-31 CU CU2019000006A patent/CU24568B1/es unknown
- 2017-07-31 IL IL264592A patent/IL264592B2/en unknown
- 2017-07-31 AU AU2017306069A patent/AU2017306069B2/en active Active
- 2017-07-31 CA CA3122348A patent/CA3122348A1/en active Pending
- 2017-07-31 CA CA3173979A patent/CA3173979A1/en active Pending
- 2017-07-31 CA CA3031980A patent/CA3031980C/en active Active
- 2017-07-31 CN CN202210980626.8A patent/CN116333147A/zh active Pending
- 2017-07-31 EP EP17837477.3A patent/EP3490603A4/en active Pending
- 2017-07-31 MX MX2019000965A patent/MX2019000965A/es unknown
- 2017-07-31 JP JP2019505253A patent/JP6971306B2/ja active Active
- 2017-07-31 KR KR1020227010743A patent/KR102624948B1/ko active IP Right Grant
- 2017-07-31 GE GEAP201715019A patent/GEP20247593B/en unknown
- 2017-07-31 SG SG11201900606VA patent/SG11201900606VA/en unknown
- 2017-07-31 CN CN201780047995.9A patent/CN109715209B/zh active Active
- 2017-07-31 CR CR20190105A patent/CR20190105A/es unknown
- 2017-07-31 PE PE2019000261A patent/PE20190389A1/es unknown
- 2017-07-31 IL IL298689A patent/IL298689B2/en unknown
- 2017-07-31 BR BR112019001247A patent/BR112019001247A2/pt active Search and Examination
- 2017-07-31 WO PCT/US2017/044714 patent/WO2018026722A1/en active Application Filing
- 2017-07-31 KR KR1020197005706A patent/KR102382804B1/ko active IP Right Grant
- 2017-08-01 UY UY0001037349A patent/UY37349A/es active IP Right Grant
-
2019
- 2019-01-22 MX MX2023000525A patent/MX2023000525A/es unknown
- 2019-01-22 MX MX2023000482A patent/MX2023000482A/es unknown
- 2019-01-23 SA SA519400950A patent/SA519400950B1/ar unknown
- 2019-01-28 PH PH12019500204A patent/PH12019500204A1/en unknown
- 2019-01-29 CL CL2019000230A patent/CL2019000230A1/es unknown
- 2019-02-12 CO CONC2019/0001212A patent/CO2019001212A2/es unknown
- 2019-02-28 EC ECSENADI201915192A patent/ECSP19015192A/es unknown
-
2020
- 2020-04-01 US US16/837,600 patent/US10745274B1/en active Active
- 2020-06-23 US US16/909,578 patent/US11027015B2/en active Active
- 2020-07-08 AU AU2020204551A patent/AU2020204551B2/en active Active
- 2020-10-06 AU AU2020250188A patent/AU2020250188B2/en active Active
-
2021
- 2021-04-27 US US17/241,628 patent/US11883493B2/en active Active
- 2021-11-01 JP JP2021178522A patent/JP7350822B2/ja active Active
- 2021-11-01 JP JP2021178521A patent/JP7350821B2/ja active Active
-
2022
- 2022-10-03 JO JOP/2022/0241A patent/JOP20220241A1/ar unknown
- 2022-10-03 JO JOP/2022/0242A patent/JOP20220242A1/ar unknown
- 2022-10-03 JO JOP/2022/0244A patent/JOP20220244A1/ar unknown
- 2022-10-03 JO JOP/2022/0245A patent/JOP20220245A1/ar unknown
- 2022-10-03 JO JOP/2022/0243A patent/JOP20220243A1/ar unknown
- 2022-10-17 AU AU2022256090A patent/AU2022256090A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019001247A2 (pt) | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo isolado ou fragmento de ligação ao antígeno do mesmo, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para produzir o anticorpo ou fragmento de ligação ao antígeno, composição, e, método de inibição da ativação do complemento da via alternativa em um mamífero. | |
ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
EA201890302A1 (ru) | Химерные рецепторы антигенов на основе однодоменных антител и способы их применения | |
BR112014018481A2 (pt) | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso | |
PH12019501973A1 (en) | Anti-phf-tau antibodies and uses thereof | |
BR112018076260A2 (pt) | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina | |
BR112015006060A2 (pt) | agentes de ligação kir3dl2 | |
BR112019010265A2 (pt) | anticorpos anti_cd137 inovadores e usos dos mesmos | |
PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
BR112017020054A2 (pt) | anticorpos para icos | |
BR112018001530A2 (pt) | anticorpo biespecífico, polinucleotídeo, vetor, célula hospedeira, métodos para produzir o anticorpo biespecífico e de inibição do crescimento de células tumorais e composição farmacêutica | |
BR112016016207A2 (pt) | Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos | |
BR112018003326A2 (pt) | anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos | |
BR112017003194B8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição | |
BR112017003582A2 (pt) | anticorpos, composições e usos | |
BR112019005316A2 (pt) | anticorpos monoclonais para morte programada 1 (pd-1) | |
BR112015025306A2 (pt) | anticorpo biespecífico, anticorpos, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira procariótica ou eucariótica e método de produção de um anticorpo | |
CO2020003882A2 (es) | Anticuerpo multiespecifico | |
BR112015029953A2 (pt) | anticorpos anti-tweakr e seus usos | |
BRPI0610197B8 (pt) | anticorpo de ligação à esclerostina, processo para a produção do mesmo, composição farmacêutica que compreende o dito anticorpo e vetor de clonagem ou expressão | |
BR112019001206A2 (pt) | anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) | |
BR112017019617A2 (pt) | Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada | |
PH12019502298A1 (en) | Monoclonal antibody to pd-l1 | |
BR112018001202A2 (pt) | anticorpo monoclonal, ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método | |
BR112016017764A2 (pt) | anticorpo antidengue de amplo espectro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07C | Technical examination (opinion): republication [chapter 7.3 patent gazette] |
Free format text: REFERENTE AO DESPACHO 7.5 NOTIFICADO NA RPI 2605, DE 08/12/2020 |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122022024546-3 PROTOCOLO 870220111418 EM 30/11/2022 17:56.O PEDIDO FOI DIVIDIDO NO BR122022024549-8 PROTOCOLO 870220111423 EM 30/11/2022 18:00. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |